Clotting factor concentrates (CFC) or bypassing agents (BPA) clinical trials

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

This study is testing a new medicine, Fitusiran, for boys aged 1 to 11 with severe haemophilia A or B. It aims to see how well it prevents bleeding and if it's safe. Some boys will receive Fitusiran for the first time, while others have already been taking it.